JP4386635B2 - 消化管間質腫瘍の処置 - Google Patents

消化管間質腫瘍の処置 Download PDF

Info

Publication number
JP4386635B2
JP4386635B2 JP2002537718A JP2002537718A JP4386635B2 JP 4386635 B2 JP4386635 B2 JP 4386635B2 JP 2002537718 A JP2002537718 A JP 2002537718A JP 2002537718 A JP2002537718 A JP 2002537718A JP 4386635 B2 JP4386635 B2 JP 4386635B2
Authority
JP
Japan
Prior art keywords
treatment
salt
patients
acid
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002537718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004512328A (ja
JP2004512328A5 (enExample
Inventor
エリーザベト・ブーフドゥンガー
ルノー・カプデヴィル
ジョージ・ダニエル・デメートリ
ササ・ディミトリジェヴィック
ブライアン・ジェイ・ドラカー
ジョナサン・エイ・フレッチャー
ヘイッキ・ヨエンスー
サンドラ・レタ・シルバーマン
デイビッド・チューブソン
マイケル・シー・ハインリック
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4386635(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2004512328A publication Critical patent/JP2004512328A/ja
Publication of JP2004512328A5 publication Critical patent/JP2004512328A5/ja
Application granted granted Critical
Publication of JP4386635B2 publication Critical patent/JP4386635B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
JP2002537718A 2000-10-27 2001-10-26 消化管間質腫瘍の処置 Expired - Lifetime JP4386635B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (3)

Publication Number Publication Date
JP2004512328A JP2004512328A (ja) 2004-04-22
JP2004512328A5 JP2004512328A5 (enExample) 2009-02-19
JP4386635B2 true JP4386635B2 (ja) 2009-12-16

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002537718A Expired - Lifetime JP4386635B2 (ja) 2000-10-27 2001-10-26 消化管間質腫瘍の処置

Country Status (25)

Country Link
US (1) US6958335B2 (enExample)
EP (1) EP1332137B1 (enExample)
JP (1) JP4386635B2 (enExample)
KR (1) KR100885129B1 (enExample)
CN (1) CN1276754C (enExample)
AT (1) ATE321556T1 (enExample)
AU (2) AU1826202A (enExample)
BR (1) BRPI0114870B8 (enExample)
CA (1) CA2424470C (enExample)
CY (1) CY1105055T1 (enExample)
CZ (1) CZ303944B6 (enExample)
DE (1) DE60118430T2 (enExample)
DK (1) DK1332137T3 (enExample)
ES (1) ES2260317T3 (enExample)
HU (1) HU229106B1 (enExample)
IL (2) IL155029A0 (enExample)
MX (1) MXPA03003703A (enExample)
NO (1) NO324948B1 (enExample)
NZ (1) NZ525254A (enExample)
PL (1) PL209733B1 (enExample)
PT (1) PT1332137E (enExample)
RU (1) RU2301066C2 (enExample)
SK (1) SK287335B6 (enExample)
WO (1) WO2002034727A2 (enExample)
ZA (1) ZA200302155B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
ES2274075T3 (es) * 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
DK1401415T3 (da) * 2001-06-29 2006-10-16 Ab Science Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
ES2274993T3 (es) * 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
ATE401078T1 (de) * 2001-09-20 2008-08-15 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
ATE404202T1 (de) * 2001-09-20 2008-08-15 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ES2269994T3 (es) * 2002-02-27 2007-04-01 Ab Science Utilizacion de inhibidores de la tirosina quinasa, para el tratamiento de los trastornos del snc.
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
MXPA06003056A (es) * 2003-09-19 2006-05-31 Novartis Ag Tratamiento de tumores estromales gastrointestinales con imatinib y midostaurin.
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
EP2061772A4 (en) * 2006-09-11 2011-06-29 Curis Inc MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP2680850B1 (en) 2011-03-04 2018-05-23 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112015001838B1 (pt) 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
AU2014296032A1 (en) 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
TW225528B (enExample) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2342222A1 (en) * 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Also Published As

Publication number Publication date
IL155029A (en) 2009-09-22
KR100885129B1 (ko) 2009-02-23
CA2424470A1 (en) 2002-05-02
JP2004512328A (ja) 2004-04-22
BR0114870A (pt) 2004-02-17
EP1332137A2 (en) 2003-08-06
CZ303944B6 (cs) 2013-07-10
PL362148A1 (en) 2004-10-18
CY1105055T1 (el) 2010-03-03
HK1058193A1 (en) 2004-05-07
ZA200302155B (en) 2004-04-22
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
HU229106B1 (en) 2013-07-29
HUP0301512A2 (hu) 2003-11-28
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
CN1276754C (zh) 2006-09-27
CA2424470C (en) 2009-06-09
CZ20031152A3 (en) 2004-04-14
ES2260317T3 (es) 2006-11-01
CN1622808A (zh) 2005-06-01
NO20031833L (no) 2003-04-24
AU2002218262B2 (en) 2005-09-29
EP1332137B1 (en) 2006-03-29
SK5182003A3 (en) 2004-02-03
AU1826202A (en) 2002-05-06
ATE321556T1 (de) 2006-04-15
BRPI0114870B8 (pt) 2021-05-25
NO324948B1 (no) 2008-01-07
US20040023976A1 (en) 2004-02-05
WO2002034727A2 (en) 2002-05-02
DE60118430D1 (de) 2006-05-18
BRPI0114870B1 (pt) 2020-06-16
NZ525254A (en) 2006-02-24
RU2301066C2 (ru) 2007-06-20
PL209733B1 (pl) 2011-10-31
KR20030051656A (ko) 2003-06-25
SK287335B6 (sk) 2010-07-07
DE60118430T2 (de) 2006-10-26
DK1332137T3 (da) 2006-07-17
MXPA03003703A (es) 2005-01-25
IL155029A0 (en) 2003-10-31

Similar Documents

Publication Publication Date Title
JP4386635B2 (ja) 消化管間質腫瘍の処置
AU2002218262A1 (en) Treatment of gastrointestinal stromal tumors
US9585893B2 (en) Flumazenil complexes, compositions comprising same and uses thereof
JP5680412B2 (ja) レオヌリンの使用およびその組成物
US9827211B2 (en) Uses and methods for the treatment of liver diseases or conditions
JP7278405B2 (ja) 小細胞肺がんの治療におけるキアウラニブの使用
WO2019242688A1 (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
KR20240006600A (ko) 투약 요법
CN118338901A (zh) 用于治疗癌症的cdk4抑制剂
HK1058193B (en) Treatment of gastrointestinal stromal tumors
JPH10175852A5 (enExample)
WO2026002224A1 (en) Method of treating polycystic ovary syndrome
TWI676477B (zh) 苯并咪唑衍生物用於夜間酸突破的用途
TW202539669A (zh) 雌激素受體降解劑之給藥方案
JP2020536846A (ja) Ｆｇｆｒ選択的チロシンキナーゼ阻害剤を含む医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20030502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081127

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20081219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090518

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090805

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090915

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090929

R150 Certificate of patent or registration of utility model

Ref document number: 4386635

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121009

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131009

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term